|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang B, Zhang S, Yue K and Wang XD: The
recurrence and survival of oral squamous cell carcinoma: A report
of 275 cases. Chin J Cancer. 32:614–618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Exarchos KP, Goletsis Y, Poli T and
Fotiadis DI: Gene expression profiling towards the prediction of
oral cancer reoccurrence. Conf Proc IEEE Eng Med Biol Soc. 2011:pp.
8307–8310. 2011; PubMed/NCBI
|
|
4
|
Saintigny P, Zhang L, Fan YH, El-Naggar
AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W and
Mao L: Gene expression profiling predicts the development of oral
cancer. Cancer Prev Res. 4:218–229. 2011. View Article : Google Scholar
|
|
5
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiery JP: Epithelial-mesenchymal
transitions in cancer onset and progression. Bull Acad Natl Med.
193:1969–1979. 2009.(In French). PubMed/NCBI
|
|
7
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
David CJ, Huang YH, Chen M, Su J, Zou Y,
Bardeesy N, Iacobuzio-Donahue CA and Massagué J: TGF-beta Tumor
suppression through a Lethal EMT. Cell. 164:1015–1030. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vincan E and Barker N: The upstream
components of the Wnt signalling pathway in the dynamic EMT and MET
associated with colorectal cancer progression. Clin Exp Metastasis.
25:657–663. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou J, Jain S, Azad AK, Xu X, Yu HC, Xu
Z, Godbout R and Fu Y: Notch and TGFβ form a positive regulatory
loop and regulate EMT in epithelial ovarian cancer cells. Cell
Signal. 28:838–849. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kong C, Wang C, Wang L, Ma M, Niu C, Sun
X, Du J, Dong Z, Zhu S, Lu J and Huang B: NEDD9 is a positive
regulator of epithelial-mesenchymal transition and promotes
invasion in aggressive breast cancer. PLoS One. 6:e226662011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kudo-Saito C, Shirako H, Takeuchi T and
Kawakami Y: Cancer metastasis is accelerated through
immunosuppression during Snail-induced EMT of cancer cells. Cancer
Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shih JY and Yang PC: The EMT regulator
slug and lung carcinogenesis. Carcinogenesis. 32:1299–1304. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harada K, Masuda S, Hirano M and Nakanuma
Y: Reduced expression of syndecan-1 correlates with histologic
dedifferentiation, lymph node metastasis, and poor prognosis in
intrahepatic cholangiocarcinoma. Hum Pathol. 34:857–863. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khotskaya YB, Dai Y, Ritchie JP, MacLeod
V, Yang Y, Zinn K and Sanderson RD: Syndecan-1 is required for
robust growth, vascularization, and metastasis of myeloma tumors in
vivo. J Biol Chem. 284:26085–26095. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Anttonen A, Kajanti M, Heikkilä P,
Jalkanen M and Joensuu H: Syndecan-1 expression has prognostic
significance in head and neck carcinoma. Br J Cancer. 79:558–564.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maeda T, Alexander CM and Friedl A:
Induction of syndecan-1 expression in stromal fibroblasts promotes
proliferation of human breast cancer cells. Cancer Res. 64:612–621.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo Q, Yang X, Ma Y and Ma L: Syndecan-1
serves as a marker for the progression of epithelial ovarian
carcinoma. Eur J Gynaecol Oncol. 36:506–513. 2015.PubMed/NCBI
|
|
19
|
Giordano RJ: Heparanase-2 and syndecan-1
in colon cancer: The ugly ducklings or the beautiful swans? Eur J
Gastroenterol Hepatol. 20:716–718. 2008.PubMed/NCBI
|
|
20
|
Moon A, Kim MS, Kim TG, Kim SH, Kim HE,
Chen YQ and Kim HR: H-ras, but not N-ras, induces an invasive
phenotype in human breast epithelial cells: A role for MMP-2 in the
H-ras-induced invasive phenotype. Int J Cancer. 85:176–181. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hsu YL, Hou MF, Kuo PL, Huang YF and Tsai
EM: Breast tumor-associated osteoblast-derived CXCL5 increases
cancer progression by ERK/MSK1/Elk-1/snail signaling pathway.
Oncogene. 32:4436–4447. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li S, Lu J, Chen Y, Xiong N, Li L, Zhang
J, Yang H, Wu C, Zeng H and Liu Y: MCP-1-induced ERK/GSK-3β/Snail
signaling facilitates the epithelial-mesenchymal transition and
promotes the migration of MCF-7 human breast carcinoma cells. Cell
Mol Immunol. 14:621–630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kurokawa H, Zhang M, Matsumoto S,
Yamashita Y, Tanaka T, Takamori K, Igawa K, Yoshida M, Fukuyama H,
Takahashi T and Sakoda S: Reduced syndecan-1 expression is
correlated with the histological grade of malignancy at the deep
invasive front in oral squamous cell carcinoma. J Oral Pathol Med.
35:301–306. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Muramatsu T, Saitoh M, Ro Y, Uekusa T,
Iwamura E, Ohta K, Kohno Y, Abiko Y and Shimono M: Inhibition of
syndecan-1 expression and function in oral cancer cells. Oncol Rep.
20:1353–1357. 2008.PubMed/NCBI
|
|
25
|
Patel S, Shah K, Mirza S, Daga A and Rawal
R: Epigenetic regulators governing cancer stem cells and
epithelial-mesenchymal transition in oral squamous cell carcinoma.
Curr Stem Cell Res Ther. 10:140–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vered M, Dayan D, Yahalom R, Dobriyan A,
Barshack I, Bello IO, Kantola S and Salo T: Cancer-associated
fibroblasts and epithelial-mesenchymal transition in metastatic
oral tongue squamous cell carcinoma. Int J Cancer. 127:1356–1362.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang CJ, Hsu CC, Chang CH, Tsai LL, Chang
YC, Lu SW, Yu CH, Huang HS, Wang JJ, Tsai CH, et al: Let-7d
functions as novel regulator of epithelial-mesenchymal transition
and chemoresistant property in oral cancer. Oncol Rep.
26:1003–1010. 2011.PubMed/NCBI
|
|
28
|
Leppä S, Vleminckx K, Van Roy F and
Jalkanen M: Syndecan-1 expression in mammary epithelial tumor cells
is E-cadherin-dependent. J Cell Sci. 109:1393–1403. 1996.PubMed/NCBI
|
|
29
|
Sun D, McAlmon KR, Davies JA, Bernfield M
and Hay ED: Simultaneous loss of expression of syndecan-1 and
E-cadherin in the embryonic palate during epithelial-mesenchymal
transformation. Int J Dev Biol. 42:733–736. 1998.PubMed/NCBI
|
|
30
|
Masola V, Gambaro G, Tibaldi E, Brunati
AM, Gastaldello A, D'Angelo A, Onisto M and Lupo A: Heparanase and
syndecan-1 interplay orchestrates fibroblast growth
factor-2-induced epithelial-mesenchymal transition in renal tubular
cells. J Biol Chem. 287:1478–1488. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Contreras HR, Ledezma RA, Vergara J,
Cifuentes F, Barra C, Cabello P, Gallegos I, Morales B, Huidobro C
and Castellón EA: The expression of syndecan-1 and −2 is associated
with Gleason score and epithelial-mesenchymal transition markers,
E-cadherin and beta-catenin, in prostate cancer. Urol Oncol.
28:534–540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Poblete CE, Fulla J, Gallardo M, Muñoz V,
Castellón EA, Gallegos I and Contreras HR: Increased SNAIL
expression and low syndecan levels are associated with high Gleason
grade in prostate cancer. Int J Oncol. 44:647–654. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Heidari-Hamedani G, Vivès RR, Seffouh A,
Afratis NA, Oosterhof A, van Kuppevelt TH, Karamanos NK, Metintas
M, Hjerpe A, Dobra K and Szatmári T: Syndecan-1 alters heparan
sulfate composition and signaling pathways in malignant
mesothelioma. Cell Signal. 27:2054–2067. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ju Ha H and Kim SJ: Association of insulin
receptor and syndecan-1 by insulin with activation of ERK I/II in
osteoblast-like UMR-106 cells. J Recept Signal Transduct Res.
33:37–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
